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Tremendous progress has been made over recent years in
the understanding of the mechanisms regulating calcium,
phosphorus, vitamin D, and parathyroid hormone
homeostasis in the normal human body and in patients with
different degrees of renal failure. In addition, some of these
findings have been translated into clinical practice, be it
diagnostic or therapeutic.
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In the August 2008 issue of the journal, a first translational
nephrology was dedicated to the role of the calcium-sensing
receptor as a major regulator of parathyroid gland function,1
and how calcimimetics may help to control secondary
hyperparathyroidism in patients with different degrees of
renal failure.2
In their review, Goodman and Quarles collected strong
arguments that signaling through the calcium-sensing
receptor has direct effects on three discrete components of
parathyroid gland function, which include parathyroid
hormone (PTH) secretion, PTH synthesis, and parathyroid
gland hyperplasia.1 Disturbances in calcium and vitamin D
metabolism that arise due to chronic kidney disease (CKD)
diminish the level of activation of the calcium-sensing
receptor leading to increases in these three components.
Each represents a physiological adaptive response by the
parathyroid glands to maintain plasma calcium homeostasis.
Studies of genetically modified mice indicate that signal
transduction via the calcium-sensing receptor is a key
determinant of parathyroid cell proliferation and parathyroid
gland hyperplasia. In contrast, there is only limited evidence
to suggest that abnormalities in phosphorus metabolism
directly affect these discrete components of parathyroid gland
function. Rather, indirect effects mediated by phosphorus-
induced alterations in calcium and/or vitamin D metabolism
are more likely to account for changes in parathyroid gland
function in CKD (Figure 1).3
Evenepoel made a critical analysis of the indications and
particularly the limitations of the use of calcimimetic agents.
Calcimimetic agents may help to control secondary hyper-
parathyroidism and to achieve more optimal mineral metabo-
lism targets in patients with CKD stage 5D.2 Whether this will
translate in its improved patient-level outcomes remains to be
shown in adequately powered prospective intervention studies.
Persistent hyperparathyroidism after successful renal transplan-
tation may become an important indication for therapy with
calcimimetics. The evidence for using calcimimetics in CKD
patients not yet on dialysis is less straightforward.
In this issue, we present our second series of bone and
mineral metabolism translational nephrology dealing with
phosphate homeostasis, its role in the regulation of PTH
secretion, the key inducing role of phosphate in the process
of vascular calcifications, and the relative efficacy of
phosphate binders.
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Serum phosphate concentrations are tightly regulated by a
steadily increasing number of factors. The disruption or
overexpression of the genes encoding the fibroblast growth
factor 23 and the multifunctional protein klotho in mice
showed their role in human phosphate physiology and in the
pathophysiology of phosphate disorders in CKD. These
experimental findings have been corroborated elegantly by
the identification of mutations in humans.
Prie´ et al. summarized the latest findings of the role of the
kidney in phosphate homeostasis. The role of the sodium-
proton exchanger regulatory factor 1 in correct targeting of
NPT2a to the apical membrane and the control of its retrieval
by PTH is discussed. The identification and the role of the
fibroblast growth factor 23–klotho axis are described, indicating
the substantial progress made in understanding the phenom-
enon of phosphate homeostasis, while at the same time asking
new questions. The early involvement of this particular axis in
the physiopathology of phosphate disturbances in chronic renal
diseases opens new therapeutic perspectives.
Silver and Naveh-Many elegantly discuss the mechanisms
whereby low P and low Ca2þ have a direct effect on the
regulation of parathyroid by inorganic phosphate. The
inorganic phosphate has a direct effect on the parathyroid,
which requires intact parathyroid-tissue architecture. The
effect of inorganic phosphate, as of Ca2þ , on PTH gene
expression is post-transcriptional and involves the regulated
interaction of parathyroid cytosolic proteins with a defined
cis-acting sequence in the PTH mRNA. Changes in serum
Ca2þ or inorganic phosphate regulate the activity of trans-
acting interacting proteins in the parathyroid, which alters
their binding to a defined 26-nucleotide cis-acting instability
sequence in the PTH mRNA 30-untranslated region. The
trans factors are either stabilizing or destabilizing factors and
their regulated binding to the PTH cis-acting element
determines the PTH mRNA half-life.
Increases in PTH mRNA stability have yet to be described,
however, either in experimental animals with elevated serum
phosphorus levels or in those ingesting diets containing
excess amounts of phosphorus, in the absence of changes in
serum levels of 1,25-dihydroxyvitamin D and Ca2þ . A
possible serum concentration P-sensing mechanism has still
to be discovered.
Calcium phosphate deposits (mostly in the form of
apatite) are found in distinct layers of the blood vessel
(intima and media), in cardiac valves, and are associated with
specific pathologies. Medial calcification is common to the
arteriosclerosis observed with age and diabetes, and is the
major form of fast developing calcifications observed in end-
stage renal disease. They play an important role in the
dramatic increase in cardiovascular mortality risk in patients
with end-stage renal disease.
Ectopic vascular calcification is a complex process, compar-
able to bone formation, governed by cell biology mechanisms as
well as physicochemical ones. Recently, O’Neill reviewed in this
journal some aspects of the physicochemical mechanisms, such
as the limitations of KDIGO-used calcium phosphorus
product threshold4 and the role of a powerful particular
calcification inhibitor pyrophosphatase.5
In the third part of this P-related translational nephrology
Giachelli describes the different aspects of the actively
regulated, genetically determined process of vascular calcifi-
cation. The key player in the initiation of that process seems
to be serum P, mainly as a consequence of an increased
phosphate load such as that observed in patients with CKD 4
and 5, and not necessarily because of outright hyperpho-
sphatemia. The potential role of the type III sodium-
dependent phosphate cotransporters Pit 1 and Pit 2 expressed
in smooth muscle cells is discussed.
Finally, what can the practicing physician do with
all these new ‘promising’ concepts? Not that much as we
can read in the conclusion of Hutchison’s review. Indeed,
three generations of phosphate binders have not been able to
answer the question of the benefits of reducing serum
phosphate in ESRF patients, let alone patients with CKD 4
and 5. High-quality comparative randomized controlled
trials are badly needed, making the plethora of ‘biochemical
target’ studies obsolete.
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Figure 1 | Phosphorus-induced alterations in calcium and/or
vitamin D metabolism change parathyroid gland function in
chronic kidney disease. 1, CASR: cell suface G protein–coupled
receptor of extracellular ionized Ca2þ ; 2, vitamin D receptor:
nuclear receptor controlling gene transcription; 3, putative
phosphate sensor; 4, FGF23 is a negative regulator of parathyroid
function. Adapted from Quarles.3
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